BPC-157 Mechanism of Action: Nitric Oxide & Vascular Pathways

A review of published research on BPC-157’s interactions with the nitric oxide system and angiogenic signaling

Introduction to BPC-157

Body Protection Compound-157 (BPC-157) is a 15-amino acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a segment of human gastric juice protein. Since its initial characterization in the early 1990s, it has become one of the most extensively studied cytoprotective peptides in preclinical literature, with over 100 published animal studies examining its effects on tissue repair, inflammation, and vascular function.

Among BPC-157’s proposed mechanisms, its interaction with the nitric oxide (NO) system has emerged as a central theme. Multiple research groups have demonstrated that BPC-157’s tissue-protective effects are closely tied to NO pathway modulation — but the relationship is more nuanced than simple upregulation or downregulation.

The Nitric Oxide System

Nitric oxide is a gaseous signaling molecule produced by three isoforms of nitric oxide synthase (NOS): endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). Each plays distinct roles in vascular tone, neurotransmission, and immune defense.

The balance between these isoforms determines whether NO serves protective or destructive roles. Constitutive eNOS/nNOS activity maintains vascular homeostasis, while excessive iNOS activation during inflammation produces cytotoxic NO levels that damage surrounding tissue.

BPC-157 and the NO System: Published Findings

Modulation Rather Than Simple Activation

Research from Sikiric et al. and colleagues at the University of Zagreb has consistently demonstrated that BPC-157 does not simply increase or decrease NO levels. Instead, it appears to modulate the NO system bidirectionally depending on the pathological context:

In L-NAME (NOS inhibitor) treated animal models, where NO production is blocked, BPC-157 counteracted the resulting hypertension, thrombosis, and tissue damage — suggesting it can compensate for NO deficiency through alternative or downstream pathways.

In L-arginine excess models, where NO is overproduced, BPC-157 attenuated the resulting hypotension and oxidative stress — suggesting it can also modulate excessive NO signaling.

eNOS Upregulation and Angiogenesis

Multiple studies have reported that BPC-157 promotes angiogenesis — the formation of new blood vessels — in wound models. The proposed mechanism involves upregulation of eNOS expression in endothelial cells, which increases local NO production and stimulates vascular endothelial growth factor (VEGF) signaling.

In rat models of ischemic injury, BPC-157 exposure was associated with increased vessel density, improved blood flow restoration, and elevated eNOS protein expression in affected tissues. These findings suggest that one mechanism of BPC-157’s tissue-protective effects operates through enhanced vascular supply to damaged areas.

Interaction with the VEGF Pathway

VEGF and NO operate in a positive feedback loop: VEGF stimulates eNOS activation, and NO enhances VEGF expression. BPC-157 appears to engage both arms of this loop. Published data shows increased VEGF expression in BPC-157-treated wound models, occurring alongside the observed angiogenic response.

This VEGF-NO axis activation helps explain why BPC-157 has shown effects across diverse tissue types in preclinical models — any tissue with vascular supply could theoretically effect from enhanced angiogenic signaling during repair.

Beyond Nitric Oxide: Related Pathways

Growth Factor Signaling

BPC-157’s effects extend beyond NO to encompass multiple growth factor systems. Published research has reported interactions with EGF (epidermal growth factor), FGF (fibroblast growth factor), and TGF-β pathways. The current understanding is that BPC-157 may coordinate multiple repair pathways rather than acting through a single receptor-mediated mechanism.

FAK-Paxillin Pathway

Focal adhesion kinase (FAK) and paxillin are intracellular signaling molecules critical for cell migration and tissue repair. Studies have demonstrated that BPC-157 activates FAK-paxillin signaling in tendon fibroblasts, promoting cell spreading and migration into wound areas. This pathway operates downstream of and parallel to NO signaling.

Dopamine System Interactions

An intriguing body of research connects BPC-157 to dopaminergic signaling. Studies show BPC-157 can modulate dopamine receptor function and protect against dopaminergic neurotoxicity in animal models. The connection to the NO system here is that nNOS activity in dopaminergic neurons is closely coupled to dopamine release and signaling.

Research Context and Limitations

Several important caveats apply to the current BPC-157 literature:

Preclinical only: The vast majority of published BPC-157 research consists of animal studies (primarily rodent models). No large-scale human clinical trials have been published as of 2026.

Single research group: A significant portion of the mechanistic literature originates from one research group at the University of Zagreb. While their work is published in peer-reviewed journals, independent replication by other groups would strengthen confidence in the proposed mechanisms.

Concentration-response complexity: The bidirectional NO modulation observed in animal studies makes it difficult to predict concentration-response relationships without further controlled investigation.

Receptor identification: Despite extensive functional characterization, a specific receptor for BPC-157 has not been conclusively identified. The mechanism by which a 15-amino acid peptide engages the NO system at the molecular level remains an active area of investigation.

ANKR Lab BPC-157

ANKR Lab provides research-grade BPC-157 with full Certificate of Analysis documentation including HPLC purity verification and mass spectrometry identity confirmation. Our material supports the continued investigation of BPC-157’s mechanisms by providing researchers with verified, high-purity starting material.

Disclaimer: This content summarizes published preclinical research for educational purposes. ANKR Lab products are intended for research use only and are not intended for human consumption, therapeutic application, or diagnostic use. Nothing in this article constitutes medical advice or a claim of therapeutic efficacy.